Molecular Imaging of <i>HER2</i>-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic ¹¹¹In- or ⁶⁸Ga-Labeled Affibody Molecules

Abstract

Molecular imaging using (111)In- or (68)Ga-labeled ABY-002 has the potential to localize metastatic lesions in vivo, adds qualitative information not available today by conventional imaging techniques, and may allow the HER2 status to be determined for metastases not amenable to biopsy. To our knowledge, this is the first report on clinical imaging data obtained with a non-immunoglobulin-based scaffold protein.